Dr. Oberstein on RASolute 302 and KRAS Breakthroughs in Pancreatic Cancer

In this episode of The Moonlight Shift, host Gina Mauro speaks with Paul Oberstein, MD, Director of GI Medical Oncology at NYU Langone Perlmutter Cancer Center, about findings from the phase 3 RASolute 302 trial (NCT06625320)—a major breakthrough in targeted pancreatic cancer treatment. Oberstein breaks down what these practice-changing findings mean for oncology nursing practice, clinical care, and the future of KRAS-targeted therapy.

The Trial and What the Numbers Mean

RASolute 302 evaluated daraxonrasib, a once-daily oral KRAS inhibitor, in patients with previously treated metastatic pancreatic cancer. The trial achieved a hazard ratio of 0.4 — representing approximately 60% improved efficacy over standard-of-care chemotherapy — and nearly doubled median overall survival to 13.2 months in the second-line setting. Oberstein explains that what made this result transformative was not just that the drug worked, but that it worked across the entire KRAS-mutant pancreatic cancer population rather than a defined subset. KRAS mutations are present in approximately 90% to 95% of pancreatic cancer cases.

The Floor and the Ceiling

Oberstein is direct about the limitations of the current data — the trial did not produce cures, and resistance to daraxonrasib is an emerging and active area of investigation. But he frames RASolute 302 explicitly as a floor rather than a ceiling, describing a pipeline of combination strategies targeting resistance mechanisms that could, in the best case scenario, extend disease control for years. He also addresses the side effect profile — rashes are the most common toxicity — and emphasizes that managing them will require education across treating centers as the drug moves toward FDA approval and broader clinical use.

Breakthrough or Buzzword?

The episode closes with the game segment, in which Oberstein rates five bold claims about the future of GI oncology. He calls immunotherapy plus chemotherapy in pancreatic cancer an "overhyped buzzword," rates liquid biopsy as somewhere between hype and reality, and expresses measured optimism about early detection — while noting that the timeline is longer than the field anticipates. His closing message: the future of treating GI cancers is going to look dramatically different in the next five to ten years, and he invites everyone to be part of it.

The Moonlight Shift is available on YouTube and across MJH Life Sciences’ oncology platforms. New episodes, released bi-weekly, feature leading and early-career oncologists from the Tri-State corridor in peer-level conversations about where the field is going — and what it still has to work out.